Catalyst Pharmaceuticals, Inc.

Filing receipts

“Total revenues for the three months ended March 31, 2026 and 2025 were as follows (in thousands): For the Three Months Ended March 31, Change 2026 2025 $ % FIRDAPSE® $ 98,859 $ 83,731 15,128 18.1 AGAMREE® 36,713 22,042 14,671 66.6 FYCOMPA® 13,771 35,627 (21,856 ) (61.3 ) Product revenue, net 149,343 141,400 7,943 5.6 License and other revenue 47 21 26 123.8 Total revenues $ 149,390 $ 141,421 7,969 5.6 The increase of approximately $7.9 million in net product revenue when comparing the three months ended March 31, 2026 and 2025 was primarily driven by increases in sales volumes for both FIRDAPSE® and AGAMREE®.”

“Our cash flow activities are summarized as follows (in thousands): For the Three Months Ended March 31, 2026 2025 Net cash provided by operating activities $ 59,587 $ 60,043 Net cash used in investing activities (27 ) — Net cash provided by (used in) financing activities (12,872 ) 3,060 Net increase in cash and cash equivalents $ 46,688 $ 63,103 The decrease in net cash provided by operating activities for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily due to a $12.5 million sales-based milestone payment due upon the achievement of AGAMREE® net revenues of $100 million in a fiscal year, which was achieved in the fourth quarter of 2025 a...”

“2026 compared to the three months ended March 31, 2025 was primarily due to a $12.5 million sales-based milestone payment due upon the achievement of AGAMREE® net revenues of $100 million in a fiscal year, which was achieved in the fourth quarter of 2025 and paid in the first quarter of 2026.”